Search company, investor...
Supernus Pharmaceuticals company logo

Supernus Pharmaceuticals

supernus.com

Founded Year

1990

Stage

IPO | IPO

Total Raised

$60M

Date of IPO

5/1/2012

Market Cap

2.18B

Stock Price

41.06

Revenue

$0000 

About Supernus Pharmaceuticals

Supernus Pharmaceuticals (NASDAQ: SUPN) develops products for the treatment of central nervous system, or CNS, diseases. The company is developing several product candidates in neurology and psychiatry to address market opportunities in epilepsy and attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsive aggression. The firm was founded in 1990 and is based in Rockville, Maryland.

Headquarters Location

9715 Key West Avenue

Rockville, Maryland, 20850,

United States

301-838-2500

Missing: Supernus Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Supernus Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Supernus Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Supernus Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Supernus Pharmaceuticals Patents

Supernus Pharmaceuticals has filed 93 patents.

The 3 most popular patent topics include:

  • Amines
  • Stimulants
  • Piperidines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/12/2022

10/4/2022

Antidepressants, Stimulants, Amines, Amphetamine, Piperidines

Grant

Application Date

4/12/2022

Grant Date

10/4/2022

Title

Related Topics

Antidepressants, Stimulants, Amines, Amphetamine, Piperidines

Status

Grant

Latest Supernus Pharmaceuticals News

The Global Attention Deficit Hyperactivity Disorder Market size is expected to reach $16.9 billion by 2028, rising at a market growth of 4.0% CAGR during the forecast period

Dec 20, 2022

Lyon, FRANCE New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Attention Deficit Hyperactivity Disorder Market Size, Share & Industry Trends Analysis Report By Drug Type, By Demographics, By Distribution Channel, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06374100/?utm_source=GNW Children with ADHD might struggle to focus, manage impulsive behaviors (doing without considering the consequences), or be highly active. This disorder is also called as hyperkinetic disorder (HKD). It is normal for kids to struggle with their manners and attention spans occasionally. The symptoms persist, can be unpleasant, and make it difficult to interact with friends, family, or co-workers. As a significant public health issue, ADHD has been linked to a wide range of adverse health outcomes for those affected and considerable cost burdens for their families and societies at large. As a result, children’s ADHD prevalence has come under scrutiny, and understanding it is essential for future service planning, training, resource allocation, and research goals. According to several reviews, prevalence rates among adolescents and children worldwide ranged widely, from as low as almost 1% to as significant as over 20%. The most widely used criteria for ADHD are those found in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) published by the American Psychiatric Association. These criteria divide ADHD into three subtypes based on the predominating symptom pattern: hyperactive-impulsive type, inattentive type, and combined type. The DSM-IV diagnosis of ADHD also allows for the occurrence of frequent co-occurring disorders like anxiety or depression. COVID – 19 Impact Analysis Given their susceptibility to the discomfort caused by the lockdown measures and social distancing measures, people with ADHD had a terrible experience during the pandemic. These interventions caused people with ADHD to display more behavioral issues. The prevalence of symptoms increased the discomfort for the patient as well as their families. Additionally, market players had to utilize novel medicines because necessary drugs ran out of supply due to consumers’ action of panic buying necessities as a precaution. This also applied to the treatments for ADHD. Market Growth Factors Enabling the disorder sufferer to build self-esteem and self-awareness When ADHD is left untreated, it severely threatens the patient’s well-being. As a result, the development of anxiety, depression, and bipolar disorder increases. Consequently, this also makes the situation hard for those directly involved with the sufferers. In addition, the mounting disappointments and frustrations can further accelerate the chances of forming antisocial personality disorder. Increasing recognition of behavioral therapy benefits Although there are two significant ways to treat ADHD, combining the two frequently yields the best outcomes. Therefore, medication combined with behavioral therapy provides better control of the treatment of ADHD. Recently, behavioral therapies have gained significant attention from parents who have children with ADHD. Parents and kids in this situation attend specialist lessons to manage and reduce the consequences of ADHD. Market Restraining Factors Prominent side-effects of medications While the number of studies being conducted on the curative measurements of ADHD symptoms, nothing highly effective has been found. Furthermore, the available data from previous studies lack sufficient approval for the formulas to be developed. The available medicines for ADHD, hence, are only able to treat either a specific patient group or only some symptoms. In addition, these medications do not work the same and, therefore, deliver side effects. From the collected data, it has also been found that the prominence of side effects is also highly unexpected. Drug Type Outlook Based on drug type, the attention deficit hyperactivity disorder market is categorized into stimulants and non-stimulants. The stimulants segment procured the highest revenue share in the attention deficit hyperactivity disorder market in 2021. These are the most frequently prescribed drugs for attention deficit hyperactivity disorder. These drugs may aid in maintaining mental focus and ignoring distractions. Most patients with ADHD have reported success with stimulant medications. These are usually prescribed for the treatment of severe and moderate ADHD. They might be helpful for kids, adolescents, and adults who struggle at school, home, or work. Stimulants Outlook The stimulants segment is further divided into amphetamine, methylphenidate, lisdexamfetamine, dexmethylphenidate. The amphetamine segment witnessed the largest revenue share in the attention deficit hyperactivity disorder market in 2021. Amphetamine or dextroamphetamine are potent central nervous system (CNS) stimulants. These drugs indirectly act as sympathomimetic amines and are also used for treating narcolepsy and hyperactivity other than ADHD. This class of drugs increases the focus on any activity, raises the ability to pay attention, and also assists in controlling impulsive behavioral symptoms. Non- Stimulants Outlook The non-stimulants segment is further classified into atomoxetine, guanfacine, clonidine, and others. The atomoxetine segment acquired the maximum revenue share in the attention deficit hyperactivity disorder market in 2021. Compared to other ADHD medications, atomoxetine operates differently. Atomoxetine is a selective noradrenaline reuptake inhibitor (SNRI), and hence it raises the levels of noradrenaline, which transports messages across brain cells, in the brain. By boosting this neurotransmitter, people with ADHD are able to improve focus and impulse control. Demographics Outlook On the basis of demographics, the attention deficit hyperactivity disorder market is fragmented into children (2 to 17 years of age) and adults. The children segment witnessed a substantial revenue share in the attention deficit hyperactivity disorder market in 2021. Children with ADHD find it challenging to control their impulsive behaviors, which can include anything from speech to movement to concentration. As a result, these kids are occasionally referred to as troublemakers or chastised for their laziness and lack of discipline. Distribution Channel Outlook Based on distribution channel, the attention deficit hyperactivity disorder market is segmented into retail pharmacy and hospital pharmacy. The retail pharmacy segment recorded the largest revenue share in the attention deficit hyperactivity disorder market in 2021. The majority of ADHD patients receive their care in outpatient settings, which has mainly given the segment its growth. Increased attention is also being paid to patient care initiatives to offer patients personal Electronic Health Records (EHRs) to keep track of their medical histories and receive primary care. Regional Outlook On the basis of region, the attention deficit hyperactivity disorder market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the maximum revenue share in the attention deficit hyperactivity disorder market in 2021. The widespread introduction and quick acceptance of various ADHD medications are the primary factors influencing the segment’s growth. Growth is further anticipated by better patient affordability, favorable reimbursement policies, and rising public awareness of current treatment modalities. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Johnson & Johnson (Johnson & Johnson Services, Inc.), Lupin Limited, Novartis AG, Takeda Pharmaceutical Company Limited, Mallinckrodt PLC, Purdue Pharma L.P., Aytu BioPharma, Inc. and Supernus Pharmaceuticals, Inc. Strategies deployed in Attention Deficit Hyperactivity Disorder Market Jan-2022: Eli Lilly and Company completed the acquisition of Prevail Therapeutics Inc., a gene therapy company. This acquisition forms a new manner for drug discovery and development at Lilly, broadening Lilly’s research efforts through the creation of a gene therapy program that would be strengthened by Prevail’s offerings of preclinical and clinical neuroscience assets. Jul-2021: Eli Lilly and Company took over Protomer Technologies, a private biotech company. Under this acquisition, Protomer’s glucose-sensing insulin program based on its proprietary molecular engineering of protein sensors (MEPS) platform is showing better results and Lilly would increase its diabetes portfolio with Lilly’s innovative technology. Jul-2021: Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., received FDA approval for a supplemental New Drug Application (sNDA) to modify the prescribing details for Adhansia XR® (methylphenidate hydrochloride) extended-release capsules CII. The sNDA approval was based on data from a Phase 3 Adult Laboratory Classroom (ALC), placebo-controlled, parallel-group, randomized, double-blind study analyzing the safety and accuracy of Adhansia XR in adult patients diagnosed with ADHD. Apr-2021: Supernus Pharmaceuticals, Inc. received FDA approval for Qelbree, viloxazine extended-release capsules. The product treats attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age. Qelbree serves prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile. Mar-2019: Novartis received FDA approval for Mayzent, a medicine for the treatment of adults with relapsing forms of multiple sclerosis consisting of relapsing-remitting multiple sclerosis, clinically isolated syndrome, and secondary progressive multiple sclerosis (SPMS) with active disease. The Product hinders disability progression and preserving cognition. Oct-2018: Neos Therapeutics, Inc., merged with Aytu BioPharma, Inc. got FDA approval for Cotempla XR-ODT, the first methylphenidate extended-release orally disintegrating tablet. The product treats attention-deficit/hyperactivity disorder (ADHD) in patients within the age group of 6 to 17 years old. May-2018: Novartis received FDA approval for Aimovig, a prescription medicine used for the preventive treatment of migraine in adults. The product is a novel therapeutic approach as one of the FDA-approved treatments mainly developed to stop migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R) that plays a major role in migraine. Feb-2018: Neos Therapeutics, Inc., merged with Aytu BioPharma, Inc. announced the launch of Adzenys ERTM Extended-Release Oral Suspension, creating Neos’ third ADHD product. Neos Therapeutics, Inc.’s increasing ADHD Product offerings show the strength of the company’s technology platform and Neos Therapeutics capability to develop, manufacture, and commercialize products. Scope of the Study

Supernus Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Supernus Pharmaceuticals founded?

    Supernus Pharmaceuticals was founded in 1990.

  • Where is Supernus Pharmaceuticals's headquarters?

    Supernus Pharmaceuticals's headquarters is located at 9715 Key West Avenue, Rockville.

  • What is Supernus Pharmaceuticals's latest funding round?

    Supernus Pharmaceuticals's latest funding round is IPO.

  • How much did Supernus Pharmaceuticals raise?

    Supernus Pharmaceuticals raised a total of $60M.

  • Who are the investors of Supernus Pharmaceuticals?

    Investors of Supernus Pharmaceuticals include New Enterprise Associates, OrbiMed Advisors, Abingworth and Shire.

  • Who are Supernus Pharmaceuticals's competitors?

    Competitors of Supernus Pharmaceuticals include Zogenix, Ology Bioservices, Solasia Pharma, Salix Pharmaceuticals, ANI Pharmaceuticals, Omthera Pharmaceuticals, Combinent BioMedical Systems, Sequel Pharmaceuticals, Nautilus Neuroscience, SupplyScape and 16 more.

Compare Supernus Pharmaceuticals to Competitors

A
Advent Pharmaceuticals

Advent Pharmaceuticals is a specialty pharmaceutical company focused on developing inhaled drug products using a dry powder inhalation delivery system. The products are mostly used for the treatment of asthma and other respiratory diseases.

K
Kytogenics Pharmaceuticals Limited

Kytogenics is a medical device company. It had developed the Nocc Hydrophilic Wound Dressing.Kytogenics Pharmaceuticals, Inc. is a biomedical company engaged in the development of products based on its medical device and drug delivery patented platform technology.

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

P
Piedmont Pharmaceuticals

Piedmont is a specialty pharmaceutical company focused on human and animal health therapeutics with expertise in parasitology and drug delivery systems.

E
ENTRA Pharmaceuticals

ENTRA Pharmaceuticals is a specialty pharmaceutical company developing therapies and improving existing treatments in areas with high unmet medical needs. In addition to the company's technology platform, ENTRA possesses strong expertise in preclinical and clinical drug development and commercialization.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.